Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in patient during pregnancy.

IF 2.4

Journal of Drug Assessment Pub Date : 2021-03-15 DOI:10.1080/21556660.2020.1847926

Farzan Kianersi, Heshmatollah Ghanbari, Zahra Naderi Beni, Afsaneh Naderi Beni

{"title":"Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in patient during pregnancy.","authors":"Farzan Kianersi, Heshmatollah Ghanbari, Zahra Naderi Beni, Afsaneh Naderi Beni","doi":"10.1080/21556660.2020.1847926","DOIUrl":null,"url":null,"abstract":"Purpose: To report the clinical course of a woman treated with intravitreal bevacizumab during pregnancy.Case report: A 27-year-old female with poorly controlled diabetes and a history of two previous miscarriage was referred to our hospital with sudden deterioration in visual acuity (VA) in her right eye. Ocular findings revealed severe Proliferative Diabetic Retinopathy (PDR) complicated with preretinal hemorrhages in her right eye, and after maximal Panretinal Photocoagulation (PRP) bilaterally, she was treated with intravitreal injection of bevacizumab (IVB) into the right eye. Twenty four hours after the bevacizumab injection, she reported vaginal bleeding, and ultrasound confirmed a 12-week pregnancy of which the patient was unaware. The patient suffered from pregnancy loss.Conclusion: Use of intravitreal anti-VEGF by pregnant woman may only be justified if the potential benefit outweighs the potential risk to the fetus and only if clearly needed. Intravitreal bevacizumab during pregnancy in women with a history of miscarriage should be used with caution.","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":"10 1","pages":"7-9"},"PeriodicalIF":2.4000,"publicationDate":"2021-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/dc/IJDA_10_1847926.PMC7971320.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21556660.2020.1847926","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To report the clinical course of a woman treated with intravitreal bevacizumab during pregnancy.

Case report: A 27-year-old female with poorly controlled diabetes and a history of two previous miscarriage was referred to our hospital with sudden deterioration in visual acuity (VA) in her right eye. Ocular findings revealed severe Proliferative Diabetic Retinopathy (PDR) complicated with preretinal hemorrhages in her right eye, and after maximal Panretinal Photocoagulation (PRP) bilaterally, she was treated with intravitreal injection of bevacizumab (IVB) into the right eye. Twenty four hours after the bevacizumab injection, she reported vaginal bleeding, and ultrasound confirmed a 12-week pregnancy of which the patient was unaware. The patient suffered from pregnancy loss.

Conclusion: Use of intravitreal anti-VEGF by pregnant woman may only be justified if the potential benefit outweighs the potential risk to the fetus and only if clearly needed. Intravitreal bevacizumab during pregnancy in women with a history of miscarriage should be used with caution.

查看原文本刊更多论文

妊娠期患者静脉注射血管内皮生长因子（VEGF）抑制剂。

目的：报告一名妇女在怀孕期间接受玻璃体内贝伐单抗治疗的临床过程：一名 27 岁女性因右眼视力（VA）突然下降而转诊至我院，她患有糖尿病，病情控制不佳，曾有两次流产史。眼部检查结果显示她的右眼患有严重的增殖性糖尿病视网膜病变（PDR），并伴有视网膜前出血，在进行了双侧最大限度的视网膜光凝（PRP）后，她接受了右眼玻璃体内注射贝伐单抗（IVB）治疗。注射贝伐单抗 24 小时后，她报告阴道出血，超声波检查证实她已怀孕 12 周，但患者并不知情。患者最终流产：结论：只有当潜在的益处大于对胎儿的潜在风险时，孕妇才有理由使用静脉注射抗血管内皮生长因子。有流产史的妇女在怀孕期间应慎用玻璃体内贝伐单抗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Drug Assessment PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

审稿时长

8 weeks